For in-vitro research use only. Not for human consumption.
cagrilintide 5mg+Semaglutide 5mg
CagriSema combines Cagrilintide (an amylin receptor agonist) with Semaglutide (a GLP-1 receptor agonist) to enable research into dual-pathway metabolic signaling. This combination targets amylin receptors and GLP-1 receptors simultaneously, two complementary pathways involved in appetite regulation and metabolic homeostasis.
cagrilintide 5mg+Semaglutide 5mg definition
CagriSema combines Cagrilintide (an amylin receptor agonist) with Semaglutide (a GLP-1 receptor agonist) to enable research into dual-pathway metabolic signaling. This combination targets amylin receptors and GLP-1 receptors simultaneously, two complementary pathways involved in appetite regulation and metabolic homeostasis.
No sequence is listed in the current catalog record for this product.
- CAS
- N/A
- MW
- Cagrilintide: 3976.6 g/mol + Semaglutide: 4113.58 g/mol
- Sequence
- Not listed
- Half-life
- Not listed
- Formula
- Not listed
- Purity
- ≥99% purity
- Form
- Lyophilized powder
- Class
- Dual Amylin/GLP-1 Combination
Reconstitution calculator
Estimate vial concentration and aliquot volume from the selected vial mass, solvent volume, and target research amount.
Calculations are for lab planning only and do not replace the product COA, protocol requirements, or qualified professional review. Confirm solvent compatibility before use.
Compound details.
- Molecular Weight
- Cagrilintide: 3976.6 g/mol + Semaglutide: 4113.58 g/mol
- Class
- Dual Amylin/GLP-1 Combination
- Purity
- ≥99% purity
- Physical Form
- Lyophilized powder
- Storage
- Store at -20°C (long term). Refrigerate after reconstitution.
Research context.
The CagriSema combination has been evaluated in Phase 3 clinical trials studying dual amylin/GLP-1 pathway activation. This represents a novel approach to studying how two distinct hormonal signaling systems interact in metabolic regulation.
Verification standard.
Every Nexus Laboratory batch ships with a Certificate of Analysis documenting HPLC purity (target ≥98%), mass spectrometry identity (expected versus observed mass), and endotoxin screening — verified by third-party laboratory testing and publicly archived. Review Nexus lab verification.
cagrilintide 5mg+Semaglutide 5mg is part of the Nexus GLP-1 & Metabolic catalog. GLP-1, amylin, and multi-agonist metabolic research peptides. Each listed variant is priced from the consolidated Nexus catalog and intended for qualified research use only.
TODO-COPY: replace with real compound-specific narrative.
The chemistry.
Fixed-dose combination of Cagrilintide (amylin analog) and Semaglutide (GLP-1 agonist)
Storage: Store at -20°C (long term). Refrigerate after reconstitution.
Technical specifications.
- Product Name: Cagrisema (2.5mg+2.5mg)
- Classification: Dual Amylin/GLP-1 Combination
- Structural Description: Fixed-dose combination of Cagrilintide (amylin analog) and Semaglutide (GLP-1 agonist)
- Molecular Weight: Cagrilintide: 3976.6 g/mol + Semaglutide: 4113.58 g/mol
- Purity: ≥99% (verified by HPLC and Mass Spectrometry)
- Physical Form: Lyophilized (freeze-dried) powder
- Intended Use: In-vitro research use only — not for human consumption
HPLC trace preview.
Related research compounds
Same category, mechanism overlap, and common research stack pairings.
cagrilintide 5mg+Semaglutide 5mg research FAQ.
What is cagrilintide 5mg+Semaglutide 5mg used for in research?
cagrilintide 5mg+Semaglutide 5mg is supplied for controlled in-vitro research workflows in the GLP-1 & Metabolic category. It is not labeled for human or veterinary use.
Is cagrilintide 5mg+Semaglutide 5mg HPLC verified?
cagrilintide 5mg+Semaglutide 5mg is listed with Nexus lab verification. Current catalog records show batch-specific purity context where batch COA data is available.
Which cagrilintide 5mg+Semaglutide 5mg sizes are available?
Current Nexus variants include 10mg.
Does cagrilintide 5mg+Semaglutide 5mg include a COA?
Yes. The current Nexus record links cagrilintide 5mg+Semaglutide 5mg to batch NEX-CAGRILINTIDE-5MG-PLUS-SEMAGL-2026-0020.